Please ensure Javascript is enabled for purposes of website accessibility

Why Ionis Pharmaceuticals' Stock Spiked Yesterday

By George Budwell - Jan 15, 2016 at 8:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's shares briefly gained more than 10% on Thursday.

What: Shares of the antisense drugmaker Ionis Pharmaceuticals (IONS 0.02%) rose by as much as 10.3% yesterday on heavier-than-normal volume. The stock finished the day up 9.43%, making it one of the top-performing biotech stocks during a particularly volatile trading session for the entire industry. 

So what: Despite the stock's strong finish yesterday, Ionis, and many of its biotech peers, actually started the session off by dropping by nearly 10%. While there wasn't a specific catalyst underlying this initial downward move, it is telling that these stocks --along with the iShares Nasdaq Biotechnology ETF (IBB 0.45%) -- all sank right around 10:02 am ET. Making this volatility even more interesting, the iShares Nasdaq Biotechnology ETF rebounded thereafter in a similar manner to Ionis, gaining more than 4% for the day.   

IBB Price Chart

IBB Price data by YCharts.

So, what's going on in biotech? Although it's hard to pin down an exact cause, my belief is that these wild swings are partly due to major funds rotating out of the high-risk biotech industry, combined with the influence of high-frequency trading, or HFT. After all, it's sort of odd that most of the selling across the entire industry occurred at a specific time, implying the hand of HFT at work.

Now what: These unpredictable swings in share price -- that have no obvious material basis -- might be hard to stomach, but they shouldn't deter investors from buying quality biotech stocks (like Ionis) for the long term. Ionis presently boasts over 38 ongoing clinical trials, including several blockbuster candidates like its next-generation cholesterol drug, Volanesorsen. That's why I think it's important to ignore this short-term noise, and instead, keep the big picture in mind going forward.  

George Budwell owns shares of iShares NASDAQ Biotechnology Index (ETF). The Motley Fool recommends Ionis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$45.71 (0.02%) $0.01
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$132.03 (0.45%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.